Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy

[1] Roth GA(2020)Global burden of cardiovascular diseases and risk factors, 1990–2019 J Am Coll Cardiol 76 2982-3021

[2] Mensah GA(2019)Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction JACC Heart Fail 7 65-76

[3] Johnson CO(2015)Evidence for a gastrointestinal–renal kaliuretic signaling axis in humans Kidney Int 88 1383-1391

[4] Addolorato G(2021)Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management Pharmacol Res 172 1402-1411

[5] Ammirati E(2020)Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction Eur J Heart Fail 22 245-251

[6] Baddour LM(2015)Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction Eur Heart J - Cardiovasc Pharmacother 1 499-3726

[7] Savarese G(2018)Competing-risk analysis of death and end stage kidney disease by hyperkalaemia status in non-dialysis chronic kidney disease patients receiving stable nephrology care J Clin Med 7 3599-979

[8] Xu H(2021)2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J 42 970-839

[9] Trevisan M(2019)Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality JACC Heart Fail 7 826-290

[10] Dahlström U(2021)Risk of hyperkalemia from renin–angiotensin–aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population Nephrol Dial Transplant 36 280-1004

[1] Roth GA(2020)Global burden of cardiovascular diseases and risk factors, 1990–2019 J Am Coll Cardiol 76 2982-3021

[2] Mensah GA(2019)Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction JACC Heart Fail 7 65-76

[3] Johnson CO(2015)Evidence for a gastrointestinal–renal kaliuretic signaling axis in humans Kidney Int 88 1383-1391

[4] Addolorato G(2021)Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management Pharmacol Res 172 1402-1411

[5] Ammirati E(2020)Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction Eur J Heart Fail 22 245-251

[6] Baddour LM(2015)Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction Eur Heart J - Cardiovasc Pharmacother 1 499-3726

[7] Savarese G(2018)Competing-risk analysis of death and end stage kidney disease by hyperkalaemia status in non-dialysis chronic kidney disease patients receiving stable nephrology care J Clin Med 7 3599-979

[8] Xu H(2021)2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J 42 970-839

[9] Trevisan M(2019)Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality JACC Heart Fail 7 826-290

[10] Dahlström U(2021)Risk of hyperkalemia from renin–angiotensin–aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population Nephrol Dial Transplant 36 280-1004